The purpose of such a loop would be to maintain hormone homeostasis. mTOR is frequently activated in human cancers [3 and 101]. Accumulating evidence suggests that aberrant regulation of both cell growth and metabolism significantly contribute to cancer development and progression [102]. The notion of causal changes in metabolism during cancer development is supported by the observation that obesity and diabetes are risk factors for cancer and that diet can affect tumor growth [103, 104, 105, 106 and 107]. For example, hepatic steatosis often leads Selleck Quizartinib to hepatocellular carcinoma (HCC) [108]. Also, metformin, the most commonly prescribed anti-diabetic drug, reduces the incidence of cancer [109 and 110]. As discussed

above, mTOR signaling plays a central role in metabolism. The fact that an mTOR signaling defect can cause both metabolic PLX-4720 datasheet disorders and cancer suggests that mTOR links cancer development and metabolism.

This is supported by the observation that metformin inhibits mTORC1 signaling, via activation of AMPK and REDD1 and a Rag GTPase-sensitive mechanism, in addition to reducing cancer [111, 112 and 113]. A recent study demonstrated that metformin’s anti-proliferative activity is due to a 4E-BP-dependent decrease in translation [114]. mTORC1, via inhibition of 4E-BP, appears to activate translation of pro-oncogenic mRNAs with 5′ terminal oligopyrimidine (5′TOP) motifs [115 and 116]. These data suggest that regulation of 4E-BP by mTORC1 plays a particularly important role in cell proliferation and cancer development. Further supporting

this hypothesis, rapamycin and its analogs (rapalogs), which only partly inhibit mTOR-dependent phosphorylation of 4E-BP, are only partly successful as a cancer treatment [117]. On the other hand, ATP competitive mTOR inhibitors that fully inhibit mTOR [110] and therefore also fully inhibit 4E-BP not phosphorylation have stronger antitumor effects [118]. Dowling et al. propose that mTORC1 controls cell proliferation exclusively via 4E-BP while it regulates cell growth via S6K [ 119]. This would mean that in mammalian cells control of cell size and cell cycle progression are independent of each other. However, how proliferation can occur independently of cell growth remains to be clarified. Further evidence suggesting that mTOR links metabolism and cancer is provided by a recent study demonstrating that LTsc1KO mice with hyperactive mTORC1 signaling display metabolic abnormalities, including defects in glucose and lipid homeostasis, and subsequently develop HCC [ 69••, 70•• and 120•]. Interestingly, liver-specific Pten knockout mice, which also exhibit increased mTORC1 activity, develop hepatic steatosis before the onset of liver cancer [ 121]. The tumor suppressor PTEN is also a negative regulator of mTORC2, and mTORC2 is required for the development of prostate cancer induced by Pten loss [ 122].